Newsletter #4: Forward pulse
“Forward pulse” – This new edition looks back on the key highlights of the second half of 2025, a period of strong momentum for Movmedix, driven by the commitment of our teams and partners worldwide.
Our newsletter
4th edition
“Forward pulse” – This new edition looks back on the key highlights of the second half of 2025, a period of strong momentum for Movmedix, driven by the commitment of our teams and partners worldwide.
International expansion, medical education initiatives, product portfolio development, regulatory milestones, organizational growth, and valuable moments shared with our team – this newsletter captures a year defined by progress, collaboration, and a clear long-term vision.
Have a read and see how we’re shaping the future, together !
A message from our CEO, Hervé Legrand
Dear all,
As we reach the end of this remarkable year, I want to share a simple message: 2025 was a year of momentum, and we created this momentum together.
Growing, Learning, Expanding
We strengthened our leadership in China, the heart of our business, while taking bold steps toward becoming a global company. From progress on U.S. registration, India or Mexico to the advancement of market access in Middle-East or South-East Asia regions, each milestone brings our technologies to more patients and more surgeons around the world.
Preparing the Future of our Portfolio
This year, we honored our roots, the trusted LARS® ligament, while pushing forward the next generation: biomimetic, bioresorbable, or shoulder solutions that will define Movmedix in the coming years. What we are building is not just a product line, but a long-term vision of regenerative sports medicine.
Strengthening our Foundations
Our teams in France and China continued to grow, improve processes, and adapt to the speed of our expansion. Movmedix is no longer a small company, it is becoming a solid, international, mission-driven company. And as we evolve, so does our organization, to better support our people and our ambitions.
A Year of Collaboration & Trust
I want to thank each of you, employees, distributors, surgeons, and our shareholder, for the trust you place in us. Every surgery performed, every distributor meeting, every R&D experiment, every production shift, every regulatory step… all of it contributes to the same mission: giving patients back the freedom to move.
Looking Ahead to 2026
Next year will be defining: FDA clearance in the U.S., new country launches, progress on our next-gen ligament, and continued growth of our teams. It will be intense, but also full of opportunity. And we are ready.
Thank you all for your energy, your partnership, and your belief in what Movmedix can achieve. I wish you and your loved ones a wonderful end of the year and I look forward to everything we will accomplish together in 2026.
About Movmedix
Driven by our vision to restore infinite mobility to patients suffering from soft tissue injuries, Movmedix continues to evolve toward becoming a global leader in sports medicine. With more than three decades of expertise, we have been at the forefront of the artificial ligament field — pioneering free-fibre technology and designing implants tailored to specific clinical indications.
Building on the strong legacy of our LARS® (Ligament Advanced Reinforcement System) product range, we remain committed to developing innovative and disruptive solutions that address the evolving needs of surgeons and improve patient outcomes worldwide.
